Bluejay Diagnostics (BJDX) CEO Indranil Dey Receives 28,000 RSUs

What Happened
Indranil Dey, President, CEO and a director of Bluejay Diagnostics, was awarded 28,000 restricted stock units (RSUs) on August 17, 2026. The Form 4 reports the acquisition at $0.00 per share (no cash paid). These RSUs are grants (transaction code A) and typically convert to actual shares only after any vesting conditions are met, so this is an award rather than an open-market purchase or sale.

Key Details

• Transaction date: August 17, 2026; Form 4 filed August 18, 2026 (timely filing).
• Shares/units granted: 28,000 RSUs; reported acquisition price: $0.00 (no cash exchanged).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes:
  • F1: The units are restricted stock units granted by the issuer’s board.
  • F2: Lana Management & Business Research International, LLC is an entity owned by Mr. Dey and Ms. Svetlana Dey; Mr. Dey has voting and dispositive power over shares held by that entity.
• Filing appears timely (reported one day after the transaction); no 10b5-1 plan, tax withholding, or cashless exercise noted.

Context: RSU grants are common compensation for executives and do not represent an immediate purchase or sale. The economic value to Mr. Dey will depend on future vesting schedules and Bluejay Diagnostics’ stock price when/if the RSUs convert to shares. This filing is informational and should not be taken as a direct buy/sell signal.